{"id":55915,"date":"2023-04-17T23:05:01","date_gmt":"2023-04-17T21:05:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/gamida-cells-allogeneic-cell-therapy-omisirge-omidubicel-onlv-receives-fda-approval\/"},"modified":"2023-04-17T23:05:01","modified_gmt":"2023-04-17T21:05:01","slug":"gamida-cells-allogeneic-cell-therapy-omisirge-omidubicel-onlv-receives-fda-approval","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/gamida-cells-allogeneic-cell-therapy-omisirge-omidubicel-onlv-receives-fda-approval\/","title":{"rendered":"Gamida Cell\u2019s Allogeneic Cell Therapy Omisirge\u00ae (omidubicel-onlv) Receives FDA Approval"},"content":{"rendered":"
\n

\nOmisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant<\/i><\/p>\n

\nGlobal, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and fungal infections as compared to standard cord blood<\/i><\/p>\n

\nOmisirge may increase access to stem cell transplant, including among patients <\/i>from diverse backgrounds<\/i><\/p>\n

\nConference call April 18 at 8 am ET<\/i><\/p>\n

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd.<\/a> (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell\u2019s allogeneic cell therapy, Omisirge\u00ae<\/sup> (omidubicel-onlv), for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.<\/p>\n

<\/a><\/p>\n

\nOmisirge received breakthrough therapy designation, priority review and orphan drug designation from the FDA, reflecting the unmet need for additional donor sources for stem cell transplant. It is the first allogeneic stem cell transplant therapy to be approved on the basis of a global, randomized Phase 3 clinical study. Please see the accompanying full Prescribing Information<\/a> for more information.<\/p>\n

\n\u201cFDA approval of Omisirge is a major advancement in the treatment of patients with hematologic malignancies that we believe may increase access to stem cell transplant and help improve patient outcomes,\u201d said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. \u201cWe are grateful to all the clinicians, patients and the entire Gamida Cell team without whom this approval would not have been possible. We also acknowledge the key role the FDA has played in supporting the development of Omisirge and other innovative and potentially life-saving cell therapies for patients with cancer and other serious diseases.\u201d<\/p>\n

\nIn a global, randomized Phase 3 clinical study, Omisirge demonstrated a median time to neutrophil recovery of 12 days in the intent to treat population, compared to 22 days for standard cord blood (p<0.001).1<\/sup> Incidence of Grade 2\/3 bacterial or Grade 3 fungal infections through 100 days following transplantation occurred in 39% of patients in the Omisirge arm and 60% of patients in the standard cord blood arm.1<\/sup> The full Phase 3 clinical study results are available in Blood<\/i><\/a>,<\/i> the official journal of the American Society of Hematology. The safety profile for Omisirge is consistent with the expected adverse events of allogeneic hematopoietic stem cell transplantation following myeloablative conditioning. Among 117 patients who received Omisirge for any disease, infusion reactions occurred in 47% of patients (Grade 3 or 4 in 15%), acute graft-versus-host disease (GvHD) in 58% (Grade III-IV in 17%), chronic GvHD in 35% and graft failure in 3%.2<\/sup><\/p>\n

\nMore than 40% of the patients in the Omisirge Phase 3 study were racially and ethnically diverse,1<\/sup> underscoring the degree to which Omisirge may help address health disparities in stem cell transplantation.<\/p>\n

\n\u201cThe approval of Omisirge is a significant development in hematopoietic stem cell transplantation,\u201d said Steven M. Devine, M.D., Chief Medical Officer at the National Marrow Donor Program\u00ae<\/sup> (NMDP)\/Be The Match\u00ae<\/sup>. <\/b>\u201cPatients who are Black or African American have just a 29% chance of finding a match via the donor registry vs. a 79% chance for patients who are White.3<\/sup> Adding Omisirge as a new donor source may help increase access to stem cell transplant for patients from racially or ethnically diverse backgrounds who struggle to find a fully matched donor in the registry.\u201d<\/p>\n

\nAllogeneic hematopoietic stem cell transplantation offers a potentially curative option for hematologic malignancies including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and myelodysplastic syndromes. Allogeneic transplant uses cells from a donor other than the recipient.<\/p>\n

\nOmisirge is manufactured to enhance and expand the number of progenitor cells utilizing proprietary nicotinamide (NAM) technology. This process produces enriched hematopoietic progenitor cells, leading to preservation of their stemness, homing to the bone marrow and retained engraftment capacity.<\/p>\n

\nOmisirge is manufactured in Gamida Cell\u2019s state-of-the-art, fully licensed GMP manufacturing facility in Kiryat Gat, Israel. Omisirge is expected to be delivered to transplant centers within 30 days after the start of manufacturing. Gamida Cell Assist, a key resource for scheduling the manufacturing of Omisirge, will provide support to patients, caregivers and the hospital\u2019s transplant team at each step of the process.<\/p>\n

\nOmisirge is now available in the United States for transplant centers to order for appropriate patients. Onboarding of transplant centers is underway. As discussed in the company\u2019s March 27 earnings call, Gamida Cell is pursuing strategic partnerships to support the launch and commercialization of Omisirge. The company also announced that is has retained Moelis & Company LLC to assist in the exploration of partnerships or broader strategic alternatives that would provide additional resources to support the launch of Omisirge and associated commercial activities in the United States and rest of world.<\/p>\n

\nConference Call<\/b><\/p>\n

\nGamida Cell will host a conference call to discuss the FDA\u2019s approval of Omisirge Tuesday, April 18, at 8 am ET. To access the conference call, please register here<\/a> and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the \u201cInvestors & Media\u201d section of the Gamida Cell website at www.gamida-cell.com<\/a>. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.<\/p>\n

\nOmisirge Indication<\/b><\/p>\n

\nOmisirge is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.<\/p>\n

\nImportant Safety Information for Omisirge<\/b><\/p>\n

\nBOXED WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, AND GRAFT FAILURE<\/b><\/p>\n